# Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)

> **NCT07591753** · — · COMPLETED · sponsor: **European EGPA Study Group** · enrollment: 591 (actual)

## Conditions studied

- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)

## Interventions

- **BIOLOGICAL:** Mepolizumab 300 mg

## Key facts

- **NCT ID:** NCT07591753
- **Lead sponsor:** European EGPA Study Group
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-18
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 591 (ACTUAL)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07591753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07591753, "Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07591753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*